JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Home・Akcijų sąrašas・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

487 0.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

478.08

Max

494.96

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-72M -114M
Pardavimai	74M 287M
Pelno marža	-39.75
Darbuotojai	528
EBITDA	-68M -106M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+41.18% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-19

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.1B 11B
Ankstesnė atidarymo kaina	486.83
Ankstesnė uždarymo kaina	487

Naujienos nuotaikos

By Acuity

21%

79%

45 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

263.2 / 277.1 Palaikymas ir pasipriešinimas

Madrigal Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-02 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2026-02-02 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2026-02-02 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026-02-02 23:38; UTC

Rinkos pokalbiai

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2026-02-02 23:28; UTC

Rinkos pokalbiai

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2026-02-02 23:23; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2026-02-02 22:57; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 22:22; UTC

Įsigijimai, susijungimai, perėmimai

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2026-02-02 22:08; UTC

Rinkos pokalbiai

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2026-02-02 21:51; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-02 21:49; UTC

Uždarbis

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2026-02-02 21:39; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:36; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2026-02-02 21:34; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:28; UTC

Įsigijimai, susijungimai, perėmimai

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2026-02-02 21:23; UTC

Uždarbis

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2026-02-02 21:19; UTC

Uždarbis

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2026-02-02 21:17; UTC

Uždarbis

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2026-02-02 21:17; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:10; UTC

Uždarbis

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2026-02-02 21:08; UTC

Uždarbis

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2026-02-02 21:07; UTC

Uždarbis

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Net $608.7M >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Rev $1.41B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q Adj EPS 25c >PLTR

2026-02-02 21:05; UTC

Uždarbis

Palantir Technologies 4Q EPS 24c >PLTR

2026-02-02 20:40; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Akcijų palyginimas

Kainos pokytis

Madrigal Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

41.18% į viršų

12 mėnesių prognozė

Vidutinis 690.8 USD 41.18%

Aukščiausias 964 USD

Žemiausias 533 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Madrigal Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių Madrigal Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

263.2 / 277.1Palaikymas ir pasipriešinimas

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

45 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.